Jing Zhao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jing Zhao has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
Jing‐Jie Dai
Zhejiang Provincial Research Center for Upper Gastrointestinal Tract Cancer Zhejiang Cancer Hospital Hangzhou 310022 China
1 shared publication- Jiwei Liu
The First Affiliated Hospital of Dalian Medical University Dalian China
1 shared publication - Jun Zhao
Department of Hepatology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing 100039, China; China Military Institute of Chinese Materia, Fifth Medical Center of Chinese PLA General Hospital, Beijing, China
1 shared publication - Junxia Chen
Department of Cell Biology and Genetics, Chongqing Medical University
1 shared publication Kaixin Ding
Department of Hepatology, Fifth Medical Center of Chinese PLA General Hospital, Beijing, China
1 shared publication- Li Yuan
Zhejiang Cancer Hospital
1 shared publication
Latest Publications
- Open Access
- 19 September 2025
- Published by Wiley in Advanced Science
- Vol. 12 (45) , e17225
Skullcapflavone II Inhibits SLC1A4‐Mediated L‐Serine Uptake and Promotes Mitochondrial Damage in Gastric Cancer
Gastric cancer (GC) is one of the most lethal human malignancies worldwide. Serine metabolism is essential for meeting biosynthetic demands and regulating the redox state of GC cells. This study demonstrates that Skullcapflavone II (SkII) selectively inhibits the proliferation and metastasis of GC cells. Transcriptomic and metabolomic analyses reveal that SkII treatment significantly affects serine metabolism in GC cells, and isotope tracing experiments confirmed that SkII reduces intracellular L‐serine levels by inhibiting uptake rather than de novo synthesis. Furthermore, IHC analysis reveal significant upregulation of the L‐serine transporter SLC1A4 in GC tissues. Binding studies using PELSA, SPR, DARTS, CETSA, and MD suggest that SLC1A4 is a potential direct target of SkII. SkII‐induced disruption of serine metabolism resulted in an imbalance in GSSG/GSH, leading to increased accumulation of intracellular ROS and oxidative stress. This metabolic disruption causes mitochondrial damage, impaired energy production, and increased apoptosis in GC cells. Additionally, in vivo studies reveal that a serine and glycine deficient diet significantly enhanced the antitumor efficacy of SkII, highlighting its potential as a combinatorial therapeutic strategy. These findings provide compelling evidence that SkII is a novel candidate for targeting serine metabolism, suggesting a promising therapeutic approach for treating GC.
- 19 September 2025
- Published by Wiley in Advanced Science
- Vol. 12 (45) , e17225
Open AccessSkullcapflavone II Inhibits SLC1A4‐Mediated L‐Serine Uptake and Promotes Mitochondrial Damage in Gastric Cancer
Gastric cancer (GC) is one of the most lethal human malignancies worldwide. Serine metabolism is essential for meeting biosynthetic demands and regulating the redox state of GC cells. This study demonstrates that Skullcapflavone II (SkII) selectively inhibits the proliferation and metastasis of GC cells. Transcriptomic and metabolomic analyses reveal that SkII treatment significantly affects serine metabolism in GC cells, and isotope tracing experiments confirmed that SkII reduces intracellular L‐serine levels by inhibiting uptake rather than de novo synthesis. Furthermore, IHC analysis reveal significant upregulation of the L‐serine transporter SLC1A4 in GC tissues. Binding studies using PELSA, SPR, DARTS, CETSA, and MD suggest that SLC1A4 is a potential direct target of SkII. SkII‐induced disruption of serine metabolism resulted in an imbalance in GSSG/GSH, leading to increased accumulation of intracellular ROS and oxidative stress. This metabolic disruption causes mitochondrial damage, impaired energy production, and increased apoptosis in GC cells. Additionally, in vivo studies reveal that a serine and glycine deficient diet significantly enhanced the antitumor efficacy of SkII, highlighting its potential as a combinatorial therapeutic strategy. These findings provide compelling evidence that SkII is a novel candidate for targeting serine metabolism, suggesting a promising therapeutic approach for treating GC.
- Open Access
- 19 May 2022
- Published by Taylor & Francis in Pharmaceutical Biology
- Vol. 60 (1) , 958-967
Schisandra chinensis essential oil attenuates acetaminophen-induced liver injury through alleviating oxidative stress and activating autophagy
Schisandra chinensis (Turcz.) Baill. (Magnoliaceae) essential oil (SCEO) composition is rich in lignans that are believed to perform protective effects in the liver.This study investigates the effe...
- 19 May 2022
- Published by Taylor & Francis in Pharmaceutical Biology
- Vol. 60 (1) , 958-967
Open AccessSchisandra chinensis essential oil attenuates acetaminophen-induced liver injury through alleviating oxidative stress and activating autophagy
Schisandra chinensis (Turcz.) Baill. (Magnoliaceae) essential oil (SCEO) composition is rich in lignans that are believed to perform protective effects in the liver.This study investigates the effe...
- 1 June 2005
- Published by Elsevier in The International Journal of Biochemistry & Cell Biology
- Vol. 37 (6) , 1219-1231
Antitumor effects of human ribonuclease inhibitor gene transfected on B16 melanoma cells
- 1 June 2005
- Published by Elsevier in The International Journal of Biochemistry & Cell Biology
- Vol. 37 (6) , 1219-1231
Antitumor effects of human ribonuclease inhibitor gene transfected on B16 melanoma cells